Last reviewed · How we verify

Docetaxel: increase of the dose

Centre Oscar Lambret · Phase 2 active Small molecule

Docetaxel: increase of the dose is a Small molecule drug developed by Centre Oscar Lambret. It is currently in Phase 2 development. Also known as: Taxotere.

At a glance

Generic nameDocetaxel: increase of the dose
Also known asTaxotere
SponsorCentre Oscar Lambret
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Docetaxel: increase of the dose

What is Docetaxel: increase of the dose?

Docetaxel: increase of the dose is a Small molecule drug developed by Centre Oscar Lambret.

Who makes Docetaxel: increase of the dose?

Docetaxel: increase of the dose is developed by Centre Oscar Lambret (see full Centre Oscar Lambret pipeline at /company/centre-oscar-lambret).

Is Docetaxel: increase of the dose also known as anything else?

Docetaxel: increase of the dose is also known as Taxotere.

What development phase is Docetaxel: increase of the dose in?

Docetaxel: increase of the dose is in Phase 2.

Related